Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences Says New Data in Clinically Low-Risk Prostate Cancer Patients Backs Use of Oncotype DX Test

11/23/2021 | 11:05am EST


ę MT Newswires 2021
All news about EXACT SCIENCES CORPORATION
01/18Exact Sciences Says Data for Second-Generation Cologuard Test Show Improved Specificity..
MT
01/10Exact Sciences' Q4 Revenue Outlook Beats Estimates But Caution Warranted on Screening B..
MT
01/10EXACT SCIENCES : Announces Preliminary Fourth Quarter 2021 Results - Form 8-K
PU
01/10Exact Sciences Provides Q4, Full-Year 2021 Revenue Guidance
MT
01/10Exact Sciences Acquires PreventionGenetics for $190 Million in Cash, Stock
MT
01/10Exact Sciences Corporation Reports Preliminary Unaudited Revenue Guidance for the Fourt..
CI
01/10Exact Sciences Corp. and OncXerna Therapeutics, Inc. Announce Licensing Agreement to He..
CI
01/09Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Can..
PR
01/09Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy ..
PR
01/09Exact Sciences Corporation acquired PreventionGenetics LLC for $190 million.
CI
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 751 M - -
Net income 2021 -515 M - -
Net Debt 2021 1 330 M - -
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 13 341 M 13 341 M -
EV / Sales 2021 8,38x
EV / Sales 2022 7,47x
Nbr of Employees 4 900
Free-Float -
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 77,42 $
Average target price 126,71 $
Spread / Average Target 63,7%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
EXACT SCIENCES CORPORATION-0.53%13 341
GUARDANT HEALTH, INC.-27.46%7 375
BGI GENOMICS CO., LTD.5.13%5 955
INVITAE CORPORATION-26.59%2 538
ADAPTIVE BIOTECHNOLOGIES CORPORATION-36.03%2 533
SEEGENE, INC.-11.80%2 325